Association of anthracyclines disposition in blast cells and different tissues with treatment outcomes of AML patients could be influenced by SNPs of the anthracyclines pathway genes (such as CBR and NQO1) and the efflux transporters (ABCB1 and ABCC1) [16]. This evidence concerns the gene ABCB1 and acute myeloid leukemia.